Key result
Current drug therapies for the secondary prevention of myocardial infarction include well-established and newer agents with diverse modes of action and evidence bases for efficacy.
Answers are grounded in this paper and cite their sources.
This review summarizes the mode of action, properties, and evidence base for current drug therapies used in the secondary prevention of myocardial infarction.
Current approaches to the secondary prevention of myocardial infarction include the use of both well‐established and newer agents. Our Drug review considers their mode of action and properties and the evidence base for their efficacy, followed by sources of further information and the Datafile.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2008) studied this question. Current drug therapies for the secondary prevention of myocardial infarction include well-established and newer agents with diverse modes of action and evidence bases for efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: